findmyKOL
Clinical trialNCT07032714RecruitingPhase 1Interventional

Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

SponsorMassachusetts General HospitalEnrollment25Relapsed Refractory Multiple Myeloma (RRMM)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase 1 study to find the recommended dose and schedule of mezigdomide and talquetamab in relapsed and refractory multiple myeloma (RRMM), and to test the effects of the drugs on cancer. Cohort A will receive talquetamab + dexamethasone, then mezigdomide + talquetamab,+ dexamethasone. After Cohort A, Cohort B will evaluate mezigdomide + dexamethasone followed by step-up dosing of talquetamab (mezigdomide + talquetamab,+ dexamethasone).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, United States

    Jessica Liegel, MD
    Not, yet, recruiting
  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

    Shonali Midha, MD
    Not, yet, recruiting
  • Massachusetts General Hospital

    Boston, Massachusetts, United States

    Andrew J. Yee, MD →
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dexamethasone →MezigdomideTalquetamab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
19 Dec 2025
Primary completion
1 Jul 2027
Completion
1 Jul 2028
Last update posted
13 Apr 2026
Registered enrollment
25
Registry id
NCT07032714
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.